Norwegian biotech Zelluna has had a landmark start to 2026. Having received UK regulatory clearance to initiate its first-in-human clinical trial with lead candidate ZI-MA4-1, the company simultaneously announced a new AI-driven collaboration to engineer its next generation of cancer-targeting receptors. BioStock reached out to CEO Namir Hassan to learn more – ahead of Zelluna’s participation at BioStock Global Forum in Lund May 21.
Read the full article HERE